Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the effect of three different types of
occlusive overlays on the drug delivery of Fentanyl Transdermal Systems, 25 mcg/h
manufactured for Mylan Pharmaceuticals Inc. by Mylan Technologies Inc., and Duragesic, 25
mcg/h manufactured for Janssen Pharmaceutica by ALZA Corporation. The acute irritation of
each type of overlay worn with each fentanyl treatment was also assessed after patch removal.